Trial Profile
Prospective Observational Study to Describe Characteristics and Management of Patients With Postmenopausal Osteoporosis Treated With Prolia in Routine Clinical Practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Mar 2019
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Sponsors Amgen
- 06 Sep 2018 Results published in the Advances in Therapy
- 20 Apr 2016 Time frame for primary endpoint reduced from 24 months to 12 months.
- 27 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.